184 related articles for article (PubMed ID: 11239757)
1. CA27.29: a valuable marker for breast cancer management. A confirmatory multicentric study on 603 cases.
Gion M; Mione R; Leon AE; Lüftner D; Molina R; Possinger K; Robertson JF
Eur J Cancer; 2001 Feb; 37(3):355-63. PubMed ID: 11239757
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the diagnostic accuracy of CA27.29 and CA15.3 in primary breast cancer.
Gion M; Mione R; Leon AE; Dittadi R
Clin Chem; 1999 May; 45(5):630-7. PubMed ID: 10222349
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of serum CA27.29, CA15-3 and CEA in patients with breast cancer.
Hou MF; Chen YL; Tseng TF; Lin CM; Chen MS; Huang CJ; Huang YS; Hsieh JS; Huang TJ; Jong SB; Huang YF
Kaohsiung J Med Sci; 1999 Sep; 15(9):520-8. PubMed ID: 10561976
[TBL] [Abstract][Full Text] [Related]
4. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15-3, CA27.29, and PankoMab.
Jeschke U; Wiest I; Schumacher AL; Kupka M; Rack B; Stahn R; Karsten U; Mayr D; Friese K; Dian D
Anticancer Res; 2012 May; 32(5):2185-9. PubMed ID: 22593508
[TBL] [Abstract][Full Text] [Related]
5. CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Rack B; Jückstock J; Trapp E; Weissenbacher T; Alunni-Fabbroni M; Schramm A; Widschwendter P; Lato K; Zwingers T; Lorenz R; Tesch H; Schneeweiss A; Fasching P; Mahner S; Beckmann MW; Lichtenegger W; Janni W;
Tumour Biol; 2016 Oct; 37(10):13769-13775. PubMed ID: 27481512
[TBL] [Abstract][Full Text] [Related]
6. Thioredoxin 1 as a serum marker for breast cancer and its use in combination with CEA or CA15-3 for improving the sensitivity of breast cancer diagnoses.
Park BJ; Cha MK; Kim IH
BMC Res Notes; 2014 Jan; 7():7. PubMed ID: 24393391
[TBL] [Abstract][Full Text] [Related]
7. Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.
Nicolini A; Tartarelli G; Carpi A; Metelli MR; Ferrari P; Anselmi L; Conte M; Berti P; Miccoli P
BMC Cancer; 2006 Nov; 6():269. PubMed ID: 17116247
[TBL] [Abstract][Full Text] [Related]
8. Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen.
Daly L; Ferguson J; Cram GP; Hars V; George SL; McCarty KS; Bast RC
J Clin Oncol; 1992 Jul; 10(7):1057-65. PubMed ID: 1607912
[TBL] [Abstract][Full Text] [Related]
9. Normalization of Elevated Tumor Marker CA27-29 After Bilateral Lung Transplantation in a Patient With Breast Cancer and Idiopathic Pulmonary Fibrosis.
Copur MS; Wurdeman JM; Nelson D; Ramaekers R; Gauchan D; Crockett D
Oncol Res; 2018 Apr; 26(3):515-518. PubMed ID: 29229020
[TBL] [Abstract][Full Text] [Related]
10. The Clinical Significance of sICAM-1 in Differentiating Benign Breast Lesions from Breast Cancer.
Chen C; Chen Q; Dong Y; Liu X
Ann Clin Lab Sci; 2020 Sep; 50(5):650-656. PubMed ID: 33067211
[TBL] [Abstract][Full Text] [Related]
11. Use of CA15-3, CEA and prolactin for the primary diagnosis of breast cancer and correlation with the prognostic factors at the time of initial diagnosis.
Arslan N; Serdar M; Deveci S; Ozturk B; Narin Y; Ilgan S; Ozturk E; Ozguven MA
Ann Nucl Med; 2000 Oct; 14(5):395-9. PubMed ID: 11108173
[TBL] [Abstract][Full Text] [Related]
12. A comparison of bone-related biomarkers and CA27.29 to assess response to treatment of osseous metastatic breast cancer.
Lüfter D; Richter A; Günther S; Flath B; Akrivakis C; Geppert R; Wernecke KD; Possinger K
Anticancer Res; 2000; 20(6D):5099-105. PubMed ID: 11326676
[TBL] [Abstract][Full Text] [Related]
13. CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer.
Devine PL; Duroux MA; Quin RJ; McGuckin MA; Joy GJ; Ward BG; Pollard CW
Breast Cancer Res Treat; 1995 Jun; 34(3):245-51. PubMed ID: 7579489
[TBL] [Abstract][Full Text] [Related]
14. The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer.
Deprés-Brummer P; Itzhaki M; Bakker PJ; Hoek FJ; Veenhof KH; de Wit R
J Cancer Res Clin Oncol; 1995; 121(7):419-22. PubMed ID: 7635872
[TBL] [Abstract][Full Text] [Related]
15. Use of Granulocyte-colony Stimulating Factor During Chemotherapy and Its Association With CA27.29 and Circulating Tumor Cells-Results From the SUCCESS A Trial.
Hepp P; Fasching PA; Beckmann MW; Fehm T; Salmen J; Hagenbeck C; Jäger B; Widschwendter P; de Gregorio N; Schochter F; Mahner S; Harbeck N; Weissenbacher T; Kurt AG; Friedl TWP; Janni W; Rack B
Clin Breast Cancer; 2018 Oct; 18(5):e1103-e1110. PubMed ID: 30017795
[TBL] [Abstract][Full Text] [Related]
16. Simple method for comparing reliability of two serum tumour markers in breast carcinoma.
O'Brien DP; Gough DB; Skehill R; Grimes H; Given HF
J Clin Pathol; 1994 Feb; 47(2):134-7. PubMed ID: 8132827
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the BT-1 serum assay for breast cancer.
Whitehurst MM; Aldenderfer PH; Sooy MM; Strelkauskas AJ
Hum Antibodies; 1999; 9(3):155-60. PubMed ID: 10690628
[TBL] [Abstract][Full Text] [Related]
18. HER-2 gene amplification, serum nucleosomes, CEA and CA15.3 tumor markers in breast cancer patients.
Zeiwar MM; Zaki SM; Mohammad LA; Zidan AA; El Nagar MR
Egypt J Immunol; 2007; 14(2):29-41. PubMed ID: 20306655
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
[TBL] [Abstract][Full Text] [Related]
20. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
